Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Gut immune cells help prevent severe salmonella infections

Widely recognized as the face of food poisoning, salmonella bacteria lurk in raw meat and poultry, on pets and in unpasteurized dairy products.

7 Jul 2026

Fatal rabies case underscores need for immediate preventive treatment

Ontario's first case of fatal rabies since 1967 provides critical guidance to help prevent death from rabies in future instances.

29 Jun 2026

Study finds two effective therapies for common childhood eating disorder

The first randomized, controlled trial for a common childhood eating disorder has shown how therapists and parents can help those struggling with the condition, known as avoidant restrictive food intake disorder, or ARFID.

29 Jun 2026

Yale study offers critical clues for future norovirus treatments

As the leading cause of viral gastroenteritis worldwide, norovirus is an all too familiar ailment. Its telltale digestive upset — not to mention its reputation for being notoriously contagious — has earned it the nicknames "winter vomiting bug" and "stomach flu."

26 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Hyperemesis gravidarum increases risks for pregnancy and birth complications

Pregnant women with a severe form of nausea face increased risks for several pregnancy and birth complications, according to a new Stanford Medicine study of 2.5 million California births.

22 Jun 2026

The importance of ketones from a clinical and medical perspective

In this interview, News-Medical talks to Marcin Pacek, senior director of medical and scientific affairs in Europe for Nova Biomedical, about the importance of ketones in a medical and clinical setting.

From Nova Biomedical 15 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

Ongoing nausea in pregnancy may flag anxiety and depression risk

Persistent or severe nausea during pregnancy was linked to higher maternal anxiety and depressive symptoms across gestation. The study found little consistent evidence that nausea worsened most perinatal outcomes, suggesting it may serve mainly as a clinical warning sign for psychological burden.

25 May 2026

Specialized care helps child thrive despite chronic swallowing disorder

Today, 11-year-old Logan Fitzpatrick of Malverne, New York, spends his time playing baseball, practicing tae kwon do, painting, and cheering on the Mets and the Islanders.

22 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026

Vitamin D deficiency linked to higher postoperative breast cancer pain

Vitamin D deficiency is associated with more moderate to severe pain following breast cancer surgery and an increased consumption of opioid drugs, finds research published online in the journal Regional Anesthesia & Pain Medicine.

19 May 2026

Health experts outline symptoms and risks of shipboard hantavirus

It's one of the cruisegoer's biggest fears: a contagious disease outbreak at sea.

18 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026